DeFinium Therapeutics Inc (DFTX) Stock Price, Quote & News

Company Profile

Definium Therapeutics, Inc., a clinical biopharmaceutical company, develops novel product candidates to treat brain health disorders. The company's lead product candidates DT120, which is in phase 3 for the treatment of generalized anxiety disorder, major depressive disorder, and other brain health disorders; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of autism spectrum disorder. The company was formerly known as Mind Me...

Industry: Biotechnology

Sector: Healthcare

Phone: 212 220 6633

Website: definiumtx.com

Address:

One World Trade Center, Suite 8500, New York, United States

Defen Apr. 29 at 7:07 PM

$DFTX come on let’s bounce back Might pull some profit out of this if it subs 20 Been in for a while

1 · Reply

CantNameThatTune Apr. 29 at 4:19 PM

$MXL You all should consider yourselves incredibly fortunate. It used to be "a thing" that stocks would run to the analyst price target theday they were issued. The prevailing thought was the current price was considered undervalued. That was 25 yrs ago. In these past few years, when a price target is issued it's so insiders and analysts can dump hard and naked short into the buy rating. Take $DFTX for instance. A $40 target from Oppenheimer came last week when it was up near $24. All it has done since is go lower.

3 · Reply

Horseman23 Apr. 29 at 11:24 AM

$DFTX

0 · Reply

CantNameThatTune Apr. 28 at 7:08 PM

$DFTX You know how it works. Anything up in a down market, this particular market, is ALWAYS down the next day!!

0 · Reply

Rocketzz Apr. 28 at 4:35 PM

$DFTX sideways for the next month or so. Then build back up in June in anticipation of readouts.

0 · Reply

Beachlife22 Apr. 28 at 1:59 PM

$DFTX 😎

0 · Reply

Horseman23 Apr. 28 at 1:54 PM

$DFTX

0 · Reply

BrahmiPowered Apr. 28 at 2:35 AM

$DFTX grifters first! gotta be patient

0 · Reply

twiggs462 Apr. 28 at 1:32 AM

PANEL: Clinical Risk, Regulatory Reality and the Path to Scale - Needham Virtual Psychedelics Forum $DFTX $ATAI $CMPS https://event.summitcast.com/view/HTrbmKNKd3jrHMB6knVrhU/guest_book?session_id=nXqi2QwF47Ftq7xFM8Bt5j

2 · Reply

Lupis94 Apr. 27 at 9:36 PM

$DFTX at 15 I’ll buy some

2 · Reply

Definium Therapeutics Highlights DT120 ODT (Lysergide Tartrate) Clinical Advancements and Commercial Strategy at Investor and Analyst Day

Apr 22, 2026, 10:00 AM EDT - 7 days ago

Definium Therapeutics Transcript: Investor Day 2026

Apr 20, 2026, 4:01 PM EDT - 9 days ago

Definium Therapeutics Announces New Employee Inducement Grants

Apr 20, 2026, 2:05 PM EDT - 9 days ago

How Trump's psychedelics executive order could unlock stalled cannabis reform

ATAI CMPS HELP GHRS

Apr 20, 2026, 10:45 AM EDT - 9 days ago

Psychedelic Stocks Surge After Trump Signs Order Fast-Tracking Drug Research

ATAI CMPS GHRS

Apr 20, 2026, 8:26 AM EDT - 9 days ago

Psychedelic stocks rally with Trump's support

ATAI CMPS GHRS

Apr 20, 2026, 8:18 AM EDT - 9 days ago

Trump Signs Order to Fast-Track Psychedelic Drugs. AtaiBeckley and These Other Stocks Are Soaring.

ATAI CMPS GHRS

Apr 20, 2026, 6:43 AM EDT - 9 days ago

Psychedelic drug makers rally as Trump orders FDA to expedite reviews

ATAI CMPS ENVB GHRS HELP

Apr 18, 2026, 7:38 PM EDT - 11 days ago

Definium Therapeutics Applauds White House Executive Order to Accelerate Mental Health Innovation and Expand Access to Psychedelic Medical Treatments

Apr 16, 2026, 3:00 PM EDT - 13 days ago

Definium Therapeutics Transcript: 25th Annual Needham Virtual Healthcare Conference

Apr 9, 2026, 7:00 AM EDT - 20 days ago

Definium Therapeutics to Participate at Upcoming Investor Conferences and Events

Mar 31, 2026, 7:00 AM EDT - 4 weeks ago

New Definium Therapeutics Study Published in the Journal of Mood and Anxiety Disorders Reveals Increasing Prevalence and Burden of Generalized Anxiety Disorder in the United States

Mar 26, 2026, 7:00 AM EDT - 4 weeks ago

Definium Therapeutics to Host Investor and Analyst Day in New York on April 22, 2026

Mar 17, 2026, 3:30 PM EDT - 6 weeks ago

Definium Therapeutics Transcript: Stifel 2026 Virtual CNS Forum

Mar 11, 2026, 1:00 PM EDT - 7 weeks ago

Definium Therapeutics Transcript: Leerink Global Healthcare Conference 2026

Mar 2, 2026, 9:10 AM EST - 2 months ago

Definium Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference

Feb 26, 2026, 4:30 PM EST - 2 months ago

Definium Therapeutics Earnings Call Transcript: Q4 2025

Feb 26, 2026, 4:01 PM EST - 2 months ago

Definium Therapeutics Reports Full-Year 2025 Financial Results and Business Updates

Feb 24, 2026, 7:01 AM EST - 2 months ago

Definium Therapeutics to Participate at Upcoming Investor Conferences

Feb 19, 2026, 4:01 PM EST - 2 months ago

Definium Therapeutics to Report Full Year 2025 Financial Results on February 26, 2026

Jan 29, 2026, 7:00 AM EST - 3 months ago

Definium Therapeutics Appoints Roger Adsett to Board of Directors

Jan 20, 2026, 7:00 AM EST - 3 months ago

Definium Therapeutics Introduces Rerouting Minds, an Educational Campaign Exploring the Potential of Pharmaceutical Lysergide (LSD) in Mental Health Care

Jan 14, 2026, 5:15 PM EST - 3 months ago

Definium Therapeutics Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 13, 2026, 7:00 AM EST - 3 months ago

Definium Therapeutics Common Shares to Trade under New Nasdaq Ticker Symbol “DFTX” Effective January 15, 2026

Jan 12, 2026, 7:00 AM EST - 3 months ago

MindMed Rebrands to Definium Therapeutics, Advancing a Leading Late-Stage Psychiatry Pipeline with Three Phase 3 Readouts Expected in 2026

Dec 18, 2025, 7:01 AM EST - 4 months ago

MindMed to Present at the 44th Annual J.P. Morgan Healthcare Conference

Dec 15, 2025, 4:01 PM EST - 4 months ago

MindMed Announces New Employee Inducement Grant

Dec 3, 2025, 3:00 PM EST - 5 months ago

Definium Therapeutics Transcript: Piper Sandler 37th Annual Healthcare Conference

Dec 2, 2025, 12:30 PM EST - 5 months ago

Definium Therapeutics Transcript: Evercore ISI 8th Annual HealthCONx Conference

Dec 1, 2025, 4:01 PM EST - 5 months ago

MindMed Announces New Employee Inducement Grants

Nov 18, 2025, 7:00 AM EST - 5 months ago

Definium Therapeutics Transcript: Jefferies London Healthcare Conference 2025

Nov 12, 2025, 1:20 PM EST - 6 months ago

Definium Therapeutics Transcript: Stifel 2025 Healthcare Conference

Nov 6, 2025, 4:30 PM EST - 6 months ago

Definium Therapeutics Earnings Call Transcript: Q3 2025

Nov 6, 2025, 4:01 PM EST - 6 months ago

MindMed Reports Q3 2025 Financial Results and Business Updates

Nov 5, 2025, 7:01 AM EST - 6 months ago

MindMed to Participate in Upcoming Investor Conferences

Nov 3, 2025, 7:01 AM EST - 6 months ago

Mind Medicine (MindMed) Inc. Announces Closing of Approximately $259 Million Public Offering, Including Full Exercise of the Underwriters' Option to Purchase Additional Shares

Oct 30, 2025, 4:01 PM EDT - 6 months ago

MindMed to Report Q3 2025 Financial Results on November 6, 2025

Oct 29, 2025, 10:14 PM EDT - 6 months ago

Mind Medicine (MindMed) Inc. Announces Pricing of $225 Million Public Offering

Oct 29, 2025, 4:01 PM EDT - 6 months ago

Mind Medicine (MindMed) Inc. Announces Proposed Public Offering

Oct 13, 2025, 2:54 PM EDT - 7 months ago

Mind Medicine Analyst Cites Strong Phase 3 Pipeline For Anxiety, Depression

Sep 19, 2025, 7:00 AM EDT - 7 months ago

New MindMed Retrospective Study Presented at Psych Congress 2025 Reveals High Rates of Suicidal Ideation (SI) in Adults with Generalized Anxiety Disorder (GAD)

Sep 18, 2025, 1:00 PM EDT - 7 months ago

Definium Therapeutics Transcript: TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit

Sep 9, 2025, 3:30 PM EDT - 8 months ago

Definium Therapeutics Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 4, 2025, 11:05 AM EDT - 8 months ago

Journal of the American Medical Association (JAMA) Publishes Results from First-Ever Randomized, Placebo-Controlled Clinical Trial Assessing the Dose-Dependent Efficacy of MM120 (Lysergide D-Tartrate, LSD) in Generalized Anxiety Disorder (GAD)

Aug 28, 2025, 7:00 AM EDT - 8 months ago

MindMed to Participate in September Investor Conferences

Jul 31, 2025, 4:30 PM EDT - 9 months ago

Definium Therapeutics Earnings Call Transcript: Q2 2025

Jul 31, 2025, 4:01 PM EDT - 9 months ago

MindMed Reports Q2 2025 Financial Results and Business Updates

Jul 24, 2025, 7:00 AM EDT - 9 months ago

MindMed to Report Second Quarter 2025 Financial Results on July 31, 2025

Jun 17, 2025, 7:00 AM EDT - 11 months ago

Definium Therapeutics Transcript: H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference

Jun 12, 2025, 10:00 AM EDT - 11 months ago

Definium Therapeutics Transcript: AGM 2025

Jun 5, 2025, 12:50 PM EDT - 11 months ago

Definium Therapeutics Transcript: Jefferies Global Healthcare Conference 2025

May 28, 2025, 7:00 AM EDT - 1 year ago

MindMed to Participate in June Investor Conferences

May 27, 2025, 7:00 AM EDT - 1 year ago

MindMed Strengthens Executive Team with Appointment of Brandi Roberts, CPA, as Chief Financial Officer

May 21, 2025, 2:05 PM EDT - 1 year ago

Definium Therapeutics Transcript: RBC Capital Markets Global Healthcare Conference 2025

May 13, 2025, 7:00 AM EDT - 1 year ago

MindMed to Present at the 2025 RBC Capital Markets Global Healthcare Conference

May 8, 2025, 8:00 AM EDT - 1 year ago

Definium Therapeutics Earnings Call Transcript: Q1 2025

May 8, 2025, 7:00 AM EDT - 1 year ago

MindMed Reports First Quarter 2025 Financial Results and Recent Business Updates

Apr 24, 2025, 7:00 AM EDT - 1 year ago

MindMed to Report First Quarter 2025 Financial Results on May 8, 2025

Apr 15, 2025, 7:00 AM EDT - 1 year ago

MindMed Announces First Patient Dosed in Phase 3 Emerge Study of MM120 in Major Depressive Disorder (MDD)

Mar 17, 2025, 7:00 AM EDT - 1 year ago

MindMed Appoints Matt Wiley as Chief Commercial Officer

Mar 11, 2025, 3:40 PM EDT - 1 year ago

Definium Therapeutics Transcript: Leerink’s Global Healthcare Conference 2025

Mar 6, 2025, 8:00 AM EST - 1 year ago

Definium Therapeutics Earnings Call Transcript: Q4 2024

Mar 6, 2025, 7:00 AM EST - 1 year ago

MindMed Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Updates

Mar 4, 2025, 7:00 AM EST - 1 year ago

MindMed to Present at Leerink's Global Healthcare Conference 2025

Feb 20, 2025, 7:00 AM EST - 1 year ago

MindMed to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025

Feb 12, 2025, 9:20 AM EST - 1 year ago

Definium Therapeutics Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference 2025

Feb 4, 2025, 7:00 AM EST - 1 year ago

MindMed to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Jan 30, 2025, 7:00 AM EST - 1 year ago

MindMed Announces First Patient Dosed in Panorama, the Second Pivotal Phase 3 Study of MM120 in Generalized Anxiety Disorder

Dec 19, 2024, 7:00 AM EST - 1 year ago

MindMed to Be Added to the Nasdaq Biotechnology Index

Dec 16, 2024, 7:00 AM EST - 1 year ago

MindMed Announces First Patient Dosed in Phase 3 Voyage Study of MM120 in Generalized Anxiety Disorder (GAD)

Dec 11, 2024, 7:00 AM EST - 1 year ago

MindMed Scientific Presentations at American College of Neuropsychopharmacology (ACNP) 2024 Congress

Dec 5, 2024, 11:15 AM EST - 1 year ago

Definium Therapeutics Transcript: 7th Annual Evercore ISI HealthCONx Conference

Dec 5, 2024, 7:00 AM EST - 1 year ago

MindMed Awarded Innovation Passport Designation by the United Kingdom (UK) Innovative Licensing and Access Pathway (ILAP) Steering Group for MM120 Orally Disintegrating Tablet (ODT) for Generalized Anxiety Disorder (GAD)

Dec 3, 2024, 7:00 AM EST - 1 year ago

MindMed Appoints Javier Muniz, M.D., as Vice President of Research and Development Strategy

Nov 7, 2024, 4:30 PM EST - 1 year ago

Definium Therapeutics Earnings Call Transcript: Q3 2024

Sep 17, 2024, 10:20 AM EDT - 1 year ago

Definium Therapeutics Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

Sep 11, 2024, 12:15 PM EDT - 1 year ago

Definium Therapeutics Transcript: Baird's 2024 Global Healthcare Conference

Aug 13, 2024, 1:30 PM EDT - 1 year ago

Definium Therapeutics Transcript: Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase 2024

Aug 13, 2024, 8:00 AM EDT - 1 year ago

Definium Therapeutics Earnings Call Transcript: Q2 2024

Jun 27, 2024, 7:00 AM EDT - 1 year ago

Definium Therapeutics Transcript: H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference

Jun 10, 2024, 10:00 AM EDT - 2 years ago

Definium Therapeutics Transcript: AGM 2024

May 15, 2024, 11:00 AM EDT - 2 years ago

Definium Therapeutics Transcript: 2024 RBC Capital Markets Global Healthcare Conference

May 8, 2024, 4:30 PM EDT - 2 years ago

Definium Therapeutics Earnings Call Transcript: Q1 2024

Mar 7, 2024, 8:00 AM EST - 2 years ago

Definium Therapeutics Transcript: Study Update

Feb 28, 2024, 8:00 AM EST - 2 years ago

Definium Therapeutics Earnings Call Transcript: Q4 2023

Feb 13, 2024, 10:00 AM EST - 2 years ago

Definium Therapeutics Transcript: Oppenheimer 34th Annual Healthcare Life Sciences Conference (Virtual)

Dec 14, 2023, 8:30 AM EST - 2 years ago

Definium Therapeutics Transcript: Study Result

Nov 2, 2023, 4:30 PM EDT - 2 years ago

Definium Therapeutics Earnings Call Transcript: Q3 2023

Aug 3, 2023, 4:30 PM EDT - 2 years ago

Definium Therapeutics Earnings Call Transcript: Q2 2023

Jun 20, 2023, 9:30 AM EDT - 3 years ago

Definium Therapeutics Transcript: Analyst Day 2023

May 4, 2023, 4:30 PM EDT - 3 years ago

Definium Therapeutics Earnings Call Transcript: Q1 2023

Mar 13, 2023, 2:00 PM EDT - 3 years ago

Definium Therapeutics Transcript: Oppenheimer Healthcare Conference

Mar 9, 2023, 4:30 PM EST - 3 years ago

Definium Therapeutics Earnings Call Transcript: Q4 2022

Nov 10, 2022, 8:30 AM EST - 3 years ago

Definium Therapeutics Earnings Call Transcript: Q3 2022

Aug 11, 2022, 6:45 AM EDT - 4 years ago

Definium Therapeutics Earnings Call Transcript: Q2 2022

May 16, 2022, 4:02 AM EDT - 4 years ago

Definium Therapeutics Earnings Call Transcript: Q1 2022

Mar 28, 2022, 8:30 AM EDT - 4 years ago

Definium Therapeutics Earnings Call Transcript: Q4 2021

Nov 17, 2021, 8:00 AM EST - 4 years ago

Definium Therapeutics Earnings Call Transcript: Q3 2021

Aug 16, 2021, 4:00 PM EDT - 5 years ago

Definium Therapeutics Earnings Call Transcript: Q2 2021

Defen Apr. 29 at 7:07 PM

$DFTX come on let’s bounce back Might pull some profit out of this if it subs 20 Been in for a while

1 · Reply

CantNameThatTune Apr. 29 at 4:19 PM

3 · Reply

Horseman23 Apr. 29 at 11:24 AM

$DFTX

0 · Reply

CantNameThatTune Apr. 28 at 7:08 PM

$DFTX You know how it works. Anything up in a down market, this particular market, is ALWAYS down the next day!!

0 · Reply

Rocketzz Apr. 28 at 4:35 PM

$DFTX sideways for the next month or so. Then build back up in June in anticipation of readouts.

0 · Reply

Beachlife22 Apr. 28 at 1:59 PM

$DFTX 😎

0 · Reply

Horseman23 Apr. 28 at 1:54 PM

$DFTX

0 · Reply

BrahmiPowered Apr. 28 at 2:35 AM

$DFTX grifters first! gotta be patient

0 · Reply

twiggs462 Apr. 28 at 1:32 AM

2 · Reply

Lupis94 Apr. 27 at 9:36 PM

$DFTX at 15 I’ll buy some

2 · Reply

ItsCarRamRod Apr. 27 at 7:41 PM

$DFTX buy the rumor sell the news, exactly.

0 · Reply

Search_2312 Apr. 27 at 7:10 PM

$DFTX sell the news day.

2 · Reply

twiggs462 Apr. 27 at 6:13 PM

$DFTX The Latest Data on Psychedelic DT120 ODT With Daniel R. Karlin, MD, MA Videos|April 27, 2026 https://www.psychiatrictimes.com/view/the-latest-data-on-psychedelic-dt120-odt-with-daniel-r-karlin-md-ma Daniel R. Karlin, MD, MA, the chief medical officer of Definium Therapeutics, shared some more information about the data on DT120 and what separates it from other psychedelics, including the new information shared at their Investor and Analyst Day.

1 · Reply

BullsVSBearsVSYoMomma Apr. 27 at 6:04 PM

$DFTX It's all noise until readouts later this year.

0 · Reply

Defen Apr. 27 at 5:13 PM

$DFTX https://www.marketbeat.com/instant-alerts/q1-earnings-estimate-for-dftx-issued-by-hc-wainwright-2026-04-27/

0 · Reply

goral17 Apr. 27 at 4:57 PM

$DFTX Welp. Calls gonna expire worthless. At least my puts are printing! 🤷🏾

0 · Reply

ItsCarRamRod Apr. 27 at 4:50 PM

$DFTX looks like the euphoria is finally starting to fade.

0 · Reply

leLu83 Apr. 27 at 4:25 PM

$DFTX zero insider purchases. Just taking in salaries and free stock options. Taking loans off of them, living a life of luxury while you suffer lol. You know they laugh at you bc in their eyes you deserve it. You lack the awareness even if its right in front of you. Greed and pride are deadly sins in this game. When avoro and commodore spin off, the capitulation will be epic. You guys are living in the dark. No access to trade desks, dark pools, and true intelligence. Youre sitting ducks boys.

1 · Reply

leLu83 Apr. 27 at 4:19 PM

$DFTX no one cares they gutted their IP for their acid compound to the former ceo? This is a goong concern as well as Barrow firing EY when they found governance issues lol. Writing is on the wall boys. Dont let your greed blind you from the signals. You will get burned. Down down down she goes..

0 · Reply

leLu83 Apr. 27 at 4:18 PM

$DFTX the stigma is real and not applicable to scalable population in clinic. This is a gimic after their multi multi millionaire failure in ibogaine.

0 · Reply

Search_2312 Apr. 27 at 12:22 PM

$DFTX It will come down to how well this works on MDD. Is a leap of faith.

1 · Reply

Merlintrader Apr. 27 at 10:19 AM

$CMPS FDA, Psychedelics and the New Hunt for Sympathy Plays: , $ATAI, $HELP, $DFTX and $GHRS

0 · Reply

Market Cap	2.12B
Revenue (ttm)	0.00
Net Income (ttm)	-183.79M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.12

Volume	1,341,600
Avg Vol	1,801,418
Day's Range	N/A - N/A
Shares Out	99.70M
Stochastic %K	4%
Beta	2.44
Analysts	Strong Sell
Price Target	$38.87